Reminder of Class Action Lawsuit for Soleno Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 03 2026
0mins
Should l Buy SLNO?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action, as those who do not will not be eligible for compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns related to its DCCR drug during clinical trials, resulting in higher risks and potential legal repercussions for investors, thereby affecting the drug's commercial viability.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its successful track record, which investors should consider when selecting legal counsel.
- Investor Action Advice: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on how to participate in the lawsuit, ensuring they have appropriate legal representation in the class action.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.870
Low
75.00
Averages
110.50
High
125.00
Current: 52.870
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). VYKAT XR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Class Action Lawsuit for Soleno Therapeutics
- Class Action Notification: Rosen Law Firm reminds investors who purchased Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, to apply as lead plaintiffs by May 5, 2026, or risk not being represented in the lawsuit.
- Lawsuit Background: The lawsuit alleges that Soleno misrepresented safety concerns related to its DCCR drug in clinical trials, leading to increased safety risks and potential legal repercussions, which adversely affected the drug's commercial viability.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its successful track record and resource advantages, prompting investors to choose their legal counsel wisely.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, with participation in the class action not dependent on being a lead plaintiff, allowing investors to remain passive or hire their own counsel.
See More
Reminder for Soleno Therapeutics Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ:SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Soleno misrepresented safety concerns related to its DCCR drug during clinical trials, resulting in investors facing greater safety risks and potential legal repercussions after the drug's commercialization.
- Law Firm Advantages: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its success and resource advantages in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with a proven track record to ensure effective legal representation in class actions, avoiding firms that merely act as intermediaries.
See More
Class Action Notice for Soleno Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns related to its DCCR drug during clinical trials, including issues like fluid retention in participants, which led to investor losses once the true information was revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, while also achieving the largest securities class action settlement against a Chinese company in 2017, showcasing its strong capabilities in this field.
- Investor Guidance: Investors are advised to carefully select experienced legal counsel rather than partnering with firms that merely act as intermediaries, ensuring they receive effective legal representation in the class action.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Reminder: Hagens Berman law firm alerts investors that the lead plaintiff deadline for the securities class action against Soleno Therapeutics (NASDAQ: SLNO) is May 5, 2026, urging those who purchased shares between March 26, 2025, and November 4, 2025, and suffered losses to submit claims.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed significant safety risks associated with its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, including potential heart failure in children, misleading investors about the company's commercial viability.
- Inflated Market Metrics: While Soleno claimed that the DCCR launch
See More
Class Action Lawsuit Filed Against Soleno Therapeutics, Inc.
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against Soleno Therapeutics, alleging securities fraud and other unlawful business practices, with investors needing to apply as Lead Plaintiff by May 5, 2026.
- Stock Price Plummets: Following a report from Scorpion Capital on August 15, 2025, which labeled Soleno's sole product DCCR as overpriced and potentially unsafe for children, the stock price fell by $5.73, a decrease of 7.41%.
- Patient Death Incident: On September 10, 2025, Soleno disclosed that a patient died after taking DCCR, leading to a stock price drop of $13.49, or 19.21%, over the next two trading sessions.
- High Discontinuation Rate: During the earnings call on November 4, 2025, Soleno's CEO revealed an 8% discontinuation rate for DCCR due to adverse effects, causing the stock to fall by $16.98, a decline of 26.59%.
See More
ClaimsFiler Reminds Investors of Soleno Therapeutics Securities Lawsuit
- Lawsuit Deadline: ClaimsFiler reminds investors of Soleno Therapeutics (Nasdaq: SLNO) that they must file lead plaintiff applications by May 5, 2026, for shares purchased between March 26, 2025, and November 4, 2025, highlighting investor concerns over potential legal risks associated with the company.
- Legal Allegations Overview: Soleno and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, specifically regarding undisclosed safety concerns related to its only commercial product, DCCR, which could expose investors to greater financial losses.
- Insufficient Safety Disclosure: The lawsuit claims that the clinical trials for DCCR did not adequately disclose potential safety issues, including excessive fluid retention among participants, which could adversely affect the drug's market acceptance and the company's reputation.
- Commercial Viability Risks: Due to undisclosed safety risks, the commercial viability of DCCR is questioned, potentially leading to increased patient discontinuation rates, reduced prescriber willingness, and possible regulatory and legal repercussions, further impacting the company's financial performance.
See More
Reminder of Class Action Lawsuit for Soleno Therapeutics
- Class Action Notification: Rosen Law Firm reminds investors who purchased Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, to apply as lead plaintiffs by May 5, 2026, or risk not being represented in the lawsuit.
- Lawsuit Background: The lawsuit alleges that Soleno misrepresented safety concerns related to its DCCR drug in clinical trials, leading to increased safety risks and potential legal repercussions, which adversely affected the drug's commercial viability.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its successful track record and resource advantages, prompting investors to choose their legal counsel wisely.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, with participation in the class action not dependent on being a lead plaintiff, allowing investors to remain passive or hire their own counsel.
See More
Reminder for Soleno Therapeutics Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ:SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Soleno misrepresented safety concerns related to its DCCR drug during clinical trials, resulting in investors facing greater safety risks and potential legal repercussions after the drug's commercialization.
- Law Firm Advantages: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its success and resource advantages in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with a proven track record to ensure effective legal representation in class actions, avoiding firms that merely act as intermediaries.
See More
Class Action Notice for Soleno Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns related to its DCCR drug during clinical trials, including issues like fluid retention in participants, which led to investor losses once the true information was revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, while also achieving the largest securities class action settlement against a Chinese company in 2017, showcasing its strong capabilities in this field.
- Investor Guidance: Investors are advised to carefully select experienced legal counsel rather than partnering with firms that merely act as intermediaries, ensuring they receive effective legal representation in the class action.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Reminder: Hagens Berman law firm alerts investors that the lead plaintiff deadline for the securities class action against Soleno Therapeutics (NASDAQ: SLNO) is May 5, 2026, urging those who purchased shares between March 26, 2025, and November 4, 2025, and suffered losses to submit claims.
- Safety Risk Allegations: The lawsuit alleges that Soleno concealed significant safety risks associated with its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, including potential heart failure in children, misleading investors about the company's commercial viability.
- Inflated Market Metrics: While Soleno claimed that the DCCR launch
See More
Class Action Lawsuit Filed Against Soleno Therapeutics, Inc.
- Class Action Initiated: Pomerantz LLP has announced a class action lawsuit against Soleno Therapeutics, alleging securities fraud and other unlawful business practices, with investors needing to apply as Lead Plaintiff by May 5, 2026.
- Stock Price Plummets: Following a report from Scorpion Capital on August 15, 2025, which labeled Soleno's sole product DCCR as overpriced and potentially unsafe for children, the stock price fell by $5.73, a decrease of 7.41%.
- Patient Death Incident: On September 10, 2025, Soleno disclosed that a patient died after taking DCCR, leading to a stock price drop of $13.49, or 19.21%, over the next two trading sessions.
- High Discontinuation Rate: During the earnings call on November 4, 2025, Soleno's CEO revealed an 8% discontinuation rate for DCCR due to adverse effects, causing the stock to fall by $16.98, a decline of 26.59%.
See More
ClaimsFiler Reminds Investors of Soleno Therapeutics Securities Lawsuit
- Lawsuit Deadline: ClaimsFiler reminds investors of Soleno Therapeutics (Nasdaq: SLNO) that they must file lead plaintiff applications by May 5, 2026, for shares purchased between March 26, 2025, and November 4, 2025, highlighting investor concerns over potential legal risks associated with the company.
- Legal Allegations Overview: Soleno and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, specifically regarding undisclosed safety concerns related to its only commercial product, DCCR, which could expose investors to greater financial losses.
- Insufficient Safety Disclosure: The lawsuit claims that the clinical trials for DCCR did not adequately disclose potential safety issues, including excessive fluid retention among participants, which could adversely affect the drug's market acceptance and the company's reputation.
- Commercial Viability Risks: Due to undisclosed safety risks, the commercial viability of DCCR is questioned, potentially leading to increased patient discontinuation rates, reduced prescriber willingness, and possible regulatory and legal repercussions, further impacting the company's financial performance.
See More
